TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Bruce Morimoto, PhD
Vice President, Drug Development at Cerecin

Profile

Bruce has over 22 years of experience in leading project teams in the development of innovative medicines, as well as providing strategic guidance, designing preclinical and clinical development programs, and advancing the development of new therapies. Previously, Bruce held leadership roles at Alkahest, Celerion; and Allon Therapeutics.  His therapeutic expertise is in CNS indications like Parkinson, Alzheimer and frontotemporal dementias. He started his career on the faculty in the Chemistry Department at Purdue University where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.

Bruce Morimoto, PhD's Network

Agenda Sessions

  • Scale-up Peptide Manufacturing Case Study: Transition from Solid-phase to Liquid Phase Synthesis

    , 15:10
  • Chairperson's Remarks

    , 14:25